William D Clark bought $4,999 of IBIO
director at iBio, Inc.. 1,838 shares at an average of $2.72, traded Jan 10, 2025, filed Jan 13, 2025.
Score components
- +15RoleDirector
- 0Trade size$5k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- +15Cluster5 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-003060, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 10, 2025 | POpen-market purchase Common Stock | +1,838 | $2.72 | $4,999 | 1,838 | Jan 13, 2025 |
Related signals
Other insiders at iBio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | IBIObuy iBio, Inc. | Marc Banjak Chief Legal Officer | $23k 13,934 shares | +126% | |
| 45Moderate | iBio, Inc. | David Arkowitz director | $50k 18,382 shares | - | |
| 40Moderate | iBio, Inc. | Marc Banjak Chief Legal Officer | $25k 9,191 shares | +490% | |
| 40Moderate | iBio, Inc. | Martin Brenner See Remarks | $25k 9,191 shares | +101% | |
| 47Moderate | iBio, Inc. | Felipe Duran Chief Financial Officer | $25k 9,191 shares | +472% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.